Vimedimex Medi-Pharma JSC (HOSE:VMD)
Vietnam · Delayed Price · Currency is VND 12,400
0.00 (0.00%)
At close: Nov 3, 2026
Vimedimex Medi-Pharma JSC Income Statement
Financials in millions VND. Fiscal year is January - December.
Millions VND. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 30, 2026 | Dec '25 Dec 31, 2025 | Jan '25 Jan 1, 2025 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Dec '21 Dec 31, 2021 |
| 310,294 | 812,983 | 1,249,868 | 3,536,651 | 7,073,499 | 12,318,752 | |
Revenue Growth | -68.76% | -34.96% | -64.66% | -50.00% | -42.58% | -32.17% |
Cost of Revenue | 209,616 | 730,667 | 1,130,924 | 3,257,394 | 6,528,733 | 11,250,064 |
Gross Profit | 100,678 | 82,316 | 118,944 | 279,256 | 544,766 | 1,068,687 |
Selling, General & Admin | 21,288 | 39,599 | 113,447 | 244,237 | 512,617 | 915,955 |
Operating Expenses | 21,288 | 39,599 | 113,447 | 244,237 | 512,617 | 915,955 |
Operating Income | 79,391 | 42,716 | 5,497 | 35,019 | 32,149 | 152,733 |
Interest Expense | - | - | -3,703 | -1,749 | -5,107 | -15,745 |
Interest & Investment Income | 11,963 | 7,977 | 7,262 | 13,437 | 6,954 | 5,519 |
Currency Exchange Gain (Loss) | 29.8 | -3,020 | -6,562 | - | 12,540 | -115,776 |
Other Non Operating Income (Expenses) | 1,756 | 6,044 | 28,148 | -6,675 | 873.34 | 1,674 |
EBT Excluding Unusual Items | 93,140 | 53,718 | 30,643 | 40,031 | 47,410 | 28,404 |
Gain (Loss) on Sale of Assets | - | - | - | - | - | 29.09 |
Pretax Income | 93,140 | 53,718 | 30,643 | 40,031 | 47,410 | 28,433 |
Income Tax Expense | 17,821 | 11,290 | 7,090 | 11,768 | 12,256 | 9,084 |
Earnings From Continuing Operations | 75,319 | 42,427 | 23,553 | 28,263 | 35,154 | 19,349 |
Minority Interest in Earnings | -14,886 | -66.19 | -358.93 | -2,781 | -336.4 | 646.03 |
Net Income | 60,433 | 42,361 | 23,194 | 25,482 | 34,818 | 19,995 |
Preferred Dividends & Other Adjustments | - | - | 1,178 | - | - | - |
Net Income to Common | 60,433 | 42,361 | 22,016 | 25,482 | 34,818 | 19,995 |
Net Income Growth | 75.09% | 92.41% | -13.60% | -26.81% | 74.13% | -46.10% |
Shares Outstanding (Basic) | 15 | 15 | 15 | 15 | 15 | 15 |
Shares Outstanding (Diluted) | 15 | 15 | 15 | 15 | 15 | 15 |
Shares Change | 0.01% | - | -0.02% | 0.02% | - | - |
EPS (Basic) | 3913.82 | 2743.54 | 1425.89 | 1650.00 | 2255.00 | 1295.00 |
EPS (Diluted) | 3913.48 | 2743.54 | 1425.89 | 1650.00 | 2255.00 | 1295.00 |
EPS Growth | 75.07% | 92.41% | -13.58% | -26.83% | 74.13% | -46.10% |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 30, 2026 | Dec '25 Dec 31, 2025 | Jan '25 Jan 1, 2025 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Dec '21 Dec 31, 2021 |
Free Cash Flow | -12,664 | 10,565 | 111,673 | 5,543 | 696,919 | -442,484 |
Free Cash Flow Per Share | -820.15 | 684.23 | 7232.56 | 358.89 | 45136.46 | -28657.78 |
Dividend Per Share | 2000.000 | 2000.000 | - | - | - | - |
Dividend Growth | - | 0% | - | - | - | - |
Gross Margin | 32.45% | 10.13% | 9.52% | 7.90% | 7.70% | 8.67% |
Operating Margin | 25.59% | 5.25% | 0.44% | 0.99% | 0.45% | 1.24% |
Profit Margin | 19.48% | 5.21% | 1.76% | 0.72% | 0.49% | 0.16% |
Free Cash Flow Margin | -4.08% | 1.30% | 8.94% | 0.16% | 9.85% | -3.59% |
EBITDA | 81,137 | 46,675 | 25,136 | 53,811 | 51,400 | 171,784 |
EBITDA Margin | 26.15% | 5.74% | 2.01% | 1.52% | 0.73% | 1.39% |
D&A For EBITDA | 1,746 | 3,958 | 19,638 | 18,792 | 19,251 | 19,051 |
EBIT | 79,391 | 42,716 | 5,497 | 35,019 | 32,149 | 152,733 |
EBIT Margin | 25.59% | 5.25% | 0.44% | 0.99% | 0.45% | 1.24% |
Effective Tax Rate | 19.13% | 21.02% | 23.14% | 29.40% | 25.85% | 31.95% |
Revenue as Reported | 310,294 | 812,983 | 1,249,868 | 3,536,651 | 7,073,499 | 12,318,752 |